Amplify Treatments, Testing and Advancements ETF (GERM)
| Assets | $9.24M |
| Expense Ratio | 0.68% |
| PE Ratio | 7.10 |
| Shares Out | 500,000 |
| Dividend (ttm) | $0.24 |
| Dividend Yield | 1.29% |
| Ex-Dividend Date | Jun 27, 2024 |
| Payout Ratio | 9.18% |
| 1-Year Return | n/a |
| Volume | 415 |
| Open | 18.25 |
| Previous Close | 18.21 |
| Day's Range | 18.25 - 18.52 |
| 52-Week Low | 15.67 |
| 52-Week High | 21.41 |
| Beta | 0.79 |
| Holdings | 57 |
| Inception Date | Jun 17, 2020 |
About GERM
Fund Home PageThe Amplify Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted index of US-listed healthcare companies engaged in treatments, testing, and other medical advancements. Holdings are selected by the index committee GERM was launched on Jun 17, 2020 and is issued by Amplify Investments.
Top 10 Holdings
52.76% of assets| Name | Symbol | Weight |
|---|---|---|
| Alnylam Pharmaceuticals, Inc. | ALNY | 10.34% |
| Labcorp Holdings Inc. | LH | 6.49% |
| Quest Diagnostics Incorporated | DGX | 6.10% |
| BioNTech SE | BNTX | 4.91% |
| Moderna, Inc. | MRNA | 4.76% |
| Vaxcyte, Inc. | PCVX | 4.49% |
| ImmunityBio, Inc. | IBRX | 4.35% |
| Bio-Rad Laboratories, Inc. | BIO | 3.86% |
| Zai Lab Limited | ZLAB | 3.85% |
| Immunocore Holdings plc | IMCR | 3.61% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 27, 2024 | $0.08799 | Jun 28, 2024 |
| Mar 26, 2024 | $0.05578 | Mar 28, 2024 |
| Dec 27, 2023 | $0.0522 | Dec 29, 2023 |
| Sep 20, 2023 | $0.040 | Sep 22, 2023 |
| Jun 21, 2023 | $0.060 | Jun 23, 2023 |
| Mar 22, 2023 | $0.090 | Mar 24, 2023 |
News
Amplify ETFs Declares June Income Distributions for its ETFs
CHICAGO, June 27, 2024 (GLOBE NEWSWIRE) -- Amplify ETFs announces June income distributions for its ETFs. ETF Name Ticker Amount per Share Ex-Date Record Date Payable Date Amplify AI Powered Equity ...
Amplify ETFs Completes Acquisition to Reach $9.1 Billion AUM Across 31 ETFs
CHICAGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Amplify ETFs announced today it has completed its previously announced acquisition of ETF Managers Group (ETFMG) exchange-traded fund (ETF) assets, which con...
China ETFs Drop On Audit Enforcement
The first tranche of Chinese ADRs affected by a 2020 law has been released.
COVID Biotech ETFs Rise At Fever Pace
ETFs that look at a subsector of biotech have significantly outperformed broader biotech funds this year.
Biotech ETFs extend January gains
Biotech exchange-traded funds rallied Monday as investors continued to monitor the sector and its impact on the coronavirus pandemic. The ETFMG Treatments Testing and Advancement ETF gained 4.6% mid-m...
First Vaccine ETF Should See Halcyon Days Ahead
There was big news on the coronavirus vaccine front Monday when Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) said their vaccine delivered an impressive showing in Phase 3 trials. What Happened: Alon...
Investing in coronavirus themed ETFs which focus on companies involved in testing and treatment
ETF Managers Group CEO Sam Masucci discusses GERM an ETF that invests in companies that are focused on COVID-19 treatment and testing.
ETF Open To Close Ratio Jumps
An unusually high number of launches in June boosted the open-to-close ratio.
Novavax's 30% surge boosts biotech ETFs to best day in weeks
Exchange-traded funds with exposure to biotech stocks rocketed higher Tuesday on hopeful news about treatments for COVID-19.
New Pharma ETF Focuses on Testing and Treatment for Infectious Diseases—but Not Covid-19
The newest health care exchange-traded fund is unique in that three stalwarts of other industry funds aren’t even among its top holdings.